Drug
Vis954
Vis954: highest development phase Phase 2, developed by Otsuka. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Otsuka
Trials
| Drug | Phase | Indication |
|---|---|---|
| VIS954 NCT07904806 | Phase 2 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis |
Latest
No recent events.
Follow Vis954 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.